Biomarker services firm Synexa Life Sciences is to base its international headquarters in Dublin.
The new centre will be home to Synexa’s global business development activities and a new bioinformatics lab, and is expected to create up to 30 highly skilled jobs over the next five years.
Synexa operates biomarker research laboratories in Berlin, London and Cape Town, where the company was founded in 2003 by Irishman Paul O’Riordan (CEO) and two local scientists.
Synexa provides biomarker services to the global biotech and pharmaceutical industry.
Biomarker analysis helps drug researchers to determine and predict a new drug’s safety and efficacy profile, identify likely patient responders and non-responders, and better understand how the drug works.
The global biomarker services industry has seen strong growth since 2010, as biopharma companies invest heavily in ‘precision medicine’ solutions - a future in which medical treatment and therapies are tailored to individual patients based on their predicted response or risk of disease.
Commenting on the decision to base in Ireland, Mr O’Riordan said: "Ireland has a well-deserved reputation as one of the world’s most open and business-friendly environments, making the decision to locate our international HQ here very straightforward.
"The IDA has been extremely welcoming and professional, and Dublin’s rapidly growing ecosystem of high-tech companies, innovative research institutions and skilled young people makes it a very attractive place to build a business like ours."